Gemtuzumab-Ozogamicin

• Mechanism of Action
• Contains a monoclonal antibody directed toward CD-33 linked to a chemotherapeutic agent, allowing for targeted delivery of cytotoxic chemotherapy to CD33-positive cells.
  The chemotherapeutic agent, N-acetyl gamma calicheamicin, is activated within targeted cells and induces double-standed DNA breaks.

Clinical Use

• • Indication
  • CD33 positive acute myeloid leukaemia.
• • Adverse Effects
  • Infusion reactions
  • Hepatotoxicity
  • Haemorrhage
  • Infections